David A. Siegel Biotechnology

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
RPRX Royalty Pharma PLC	$14.8B	$93.7 Million 0.23% of portfolio	3,673,200	Q4 2024 Added 21.1%
NVO Novo Nordisk A S	$205B	$87.9 Million 0.21% of portfolio	1,021,700	Q4 2024 Added 649.05%
EXEL Exelixis, Inc.	$12.4B	$54.2 Million 0.13% of portfolio	1,627,890	Q4 2024 Reduced 4.39%
ADMA Adma Biologics, Inc.	$3.47B	$50.6 Million 0.12% of portfolio	2,950,124	Q4 2024 Reduced 33.77%
IONS Ionis Pharmaceuticals Inc	$4.79B	$47.2 Million 0.11% of portfolio	1,349,211	Q4 2024 Added 1.26%
RARE Ultragenyx Pharmaceutical Inc.	$2.86B	$38.4 Million 0.09% of portfolio	913,500	Q4 2024 Reduced 7.52%
GMAB Genmab A/S	$15.9B	$34.5 Million 0.08% of portfolio	1,653,500	Q4 2024 Added 168.82%
MRUS Merus N.V.	$2.12B	$30.3 Million 0.07% of portfolio	720,800	Q4 2024 Reduced 1.23%
NTLA Intellia Therapeutics, Inc.	$712M	$23.3 Million 0.06% of portfolio	1,998,317	Q4 2024 Added 94.46%
ACAD Acadia Pharmaceuticals Inc	$2.93B	$23.2 Million 0.06% of portfolio	1,263,200	Q4 2024 Added 160.83%
INSM Insmed Inc	$10.5B	$22.5 Million 0.05% of portfolio	326,500	Q4 2024 Reduced 16.86%
MNKD Mannkind Corp	$1.33B	$19.9 Million 0.05% of portfolio	3,092,627	Q4 2024 Added 16.78%
CORT Corcept Therapeutics Inc	$5.94B	$19.2 Million 0.05% of portfolio	381,800	Q4 2024 Reduced 16.47%
BCRX Biocryst Pharmaceuticals Inc	$1.5B	$18.8 Million 0.05% of portfolio	2,499,812	Q4 2024 Added 14.62%
ALNY Alnylam Pharmaceuticals, Inc.	$30.7B	$18.5 Million 0.04% of portfolio	78,800	Q4 2024 Reduced 23.57%
IMCR Immunocore Holdings PLC	$1.33B	$17.8 Million 0.04% of portfolio	604,900	Q4 2024 Reduced 20.17%
TVTX Travere Therapeutics, Inc.	$1.25B	$16.9 Million 0.04% of portfolio	967,500	Q4 2024 Added 34.3%
PTCT Ptc Therapeutics, Inc.	$3.72B	$16.3 Million 0.04% of portfolio	360,442	Q4 2024 Reduced 16.15%
QURE Uni Qure N.V.	$565M	$13.4 Million 0.03% of portfolio	756,900	Q4 2024 Added 1.39%
IDYA Ideaya Biosciences, Inc.	$932M	$11.8 Million 0.03% of portfolio	460,600	Q4 2024 Reduced 1.6%
XENE Xenon Pharmaceuticals Inc.	$2.31B	$11.7 Million 0.03% of portfolio	298,700	Q4 2024 Added 9.13%
SRRK Scholar Rock Holding Corp	$1.87B	$11.3 Million 0.03% of portfolio	261,400	Q4 2024 Reduced 55.84%
NUVL Nuvalent, Inc.	$3.09B	$11 Million 0.03% of portfolio	140,100	Q4 2024 Reduced 7.95%
LEGN Legend Biotech Corp	$5.81B	$10.7 Million 0.03% of portfolio	327,400	Q4 2024 Added 904.29%
CYTK Cytokinetics Inc	$4.13B	$10.6 Million 0.03% of portfolio	226,400	Q4 2024 Added 5.45%
KYMR Kymera Therapeutics, Inc.	$1.73B	$10.5 Million 0.03% of portfolio	260,300	Q4 2024 Reduced 22.6%
XNCR Xencor Inc	$830M	$10.2 Million 0.02% of portfolio	442,000	Q4 2024 Reduced 22.85%
JAZZ Jazz Pharmaceuticals PLC	$8.79B	$10.1 Million 0.02% of portfolio	81,700	Q4 2024 Reduced 22.92%
ARWR Arrowhead Pharmaceuticals, Inc.	$1.84B	$8.1 Million 0.02% of portfolio	430,700	Q4 2024 Added 330.7%
ABCL Ab Cellera Biologics Inc.	$681M	$7.64 Million 0.02% of portfolio	2,608,400	Q4 2024 Added 19.78%
MIRM Mirum Pharmaceuticals, Inc.	$1.64B	$7.21 Million 0.02% of portfolio	174,400	Q4 2024 Reduced 15.13%
CDMO Avid Bioservices, Inc.	$776M	$7.14 Million 0.02% of portfolio	577,950	Q4 2024 Reduced 25.53%
SNDX Syndax Pharmaceuticals Inc	$819M	$7.09 Million 0.02% of portfolio	535,952	Q4 2024 Reduced 19.93%
BMRN Biomarin Pharmaceutical Inc	$13.2B	$7.03 Million 0.02% of portfolio	107,014	Q4 2024 Reduced 40.98%
VRDN Viridian Therapeutics, Inc.\De	$610M	$6.43 Million 0.02% of portfolio	335,569	Q4 2024 Reduced 24.56%
NVAX Novavax Inc	$617M	$6.27 Million 0.02% of portfolio	779,700	Q4 2024 Reduced 61.0%
ALLO Allogene Therapeutics, Inc.	$278M	$5.76 Million 0.01% of portfolio	2,702,200	Q4 2024 Added 12.11%
ARVN Arvinas, Inc.	$931M	$5.42 Million 0.01% of portfolio	282,600	Q4 2024 Added 24.17%
AVXL Anavex Life Sciences Corp.	$680M	$5.27 Million 0.01% of portfolio	490,600	Q4 2024 Reduced 0.59%
MRNA Moderna, Inc.	$13.8B	$4.31 Million 0.01% of portfolio	103,700	Q4 2024 Reduced 70.91%
UTHR United Therapeutics Corp	$14.2B	$4.16 Million 0.01% of portfolio	11,800	Q4 2024 Reduced 9.93%
MGNX Macrogenics Inc	$146M	$3.64 Million 0.01% of portfolio	1,118,600	Q4 2024 Added 7.15%
INVA Innoviva, Inc.	$1.23B	$3.55 Million 0.01% of portfolio	204,500	Q4 2024 Reduced 45.94%
HRMY Harmony Biosciences Holdings, Inc.	$2B	$3.4 Million 0.01% of portfolio	98,900	Q4 2024 Added 21.8%
CRSP Crispr Therapeutics Ag	$3.42B	$3.34 Million 0.01% of portfolio	84,800	Q4 2024 Added 50.35%
CCCC C4 Therapeutics, Inc.	$119M	$3.18 Million 0.01% of portfolio	884,300	Q4 2024 Reduced 17.01%
ARDX Ardelyx, Inc.	$806M	$3.07 Million 0.01% of portfolio	593,700	Q4 2024 Added 206.66%
RXRX Recursion Pharmaceuticals, Inc.	$1.19B	$3.05 Million 0.01% of portfolio	451,745	Q4 2024 Reduced 7.79%
TARS Tarsus Pharmaceuticals, Inc.	$1.19B	$2.96 Million 0.01% of portfolio	53,500	Q4 2024 Reduced 79.13%
KOD Kodiak Sciences Inc.	$202M	$2.83 Million 0.01% of portfolio	284,200	Q4 2024 Reduced 14.73%

Shares Options

David A. Siegel

David A. Siegel is the co-founder and CEO of Two Sigma Advisers, a successful investment firm that uses technology and data-driven approaches to investing. Siegel is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track David A. Siegel's portfolio

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account